Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

810
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
810
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Ligand Binding Sites02:40

Ligand Binding Sites

11.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
11.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monovalent cation binding to model systems and the macrocyclic depsipeptide, emodepside.

Journal of computational chemistry·2024
Same author

In Pursuit of an Allosteric Human Tropomyosin Kinase A (<i>h</i>TrkA) Inhibitor for Chronic Pain.

ACS medicinal chemistry letters·2021
Same author

Synthetic inhibitor leads of human tropomyosin receptor kinase A (<i>h</i>TrkA).

RSC medicinal chemistry·2021
Same author

Connecting the conformational behavior of cyclic octadepsipeptides with their ionophoric property and membrane permeability.

Organic & biomolecular chemistry·2020
Same author

Lead identification and characterization of hTrkA type 2 inhibitors.

Bioorganic & medicinal chemistry letters·2019
Same author

Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA).

Bioorganic & medicinal chemistry letters·2019
Same journal

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026
Same journal

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design and N-terminal acylation of a lactam-cyclized 11-residue antimicrobial peptide for improved antibacterial potency.

Bioorganic & medicinal chemistry letters·2026
Same journal

Rational design, synthesis, and biological evaluation of chalcone hybrids including benzoylpiperazin (phenylacetylpiperazin)-thiophene as anti- Alzheimer's agents.

Bioorganic & medicinal chemistry letters·2026
Same journal

New aminopiperidine-azoles as antifungal agents against Candida albicans with mechanistic insights into the cAMP-PKA pathway.

Bioorganic & medicinal chemistry letters·2026
Same journal

Novel 1H-pyrrole-2,5-dione derivatives as potential anti-diabetic agents: design, synthesis, in vitro, in ovo, and molecular docking studies.

Bioorganic & medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.3K

Comprehending renin inhibitor's binding affinity using structure-based approaches.

Govindan Subramanian1, Shashidhar N Rao

  • 1VMRD Global Discovery, Zoetis, 333 Portage Street, Kalamazoo, MI 49007, USA.

Bioorganic & Medicinal Chemistry Letters
|November 19, 2013
PubMed
Summary
This summary is machine-generated.

Structure-based design (SBD) methods offer some guidance for lead optimization but struggle with precise binding affinity predictions for human renin inhibitors. Current computational approaches require further refinement for reliable quantitative accuracy in drug discovery.

Keywords:
3D-QSARIn silico modelingMD simulationMM-GB/SARenin inhibitor

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

21.4K

Related Experiment Videos

Last Updated: May 5, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms
15:27

Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms

Published on: April 17, 2017

21.4K

Area of Science:

  • Computational chemistry
  • Drug discovery
  • Structural biology

Background:

  • Structure-based design (SBD) is crucial for optimizing drug candidates.
  • Accurate prediction of binding affinity is essential for lead optimization.
  • Human renin inhibitors are a key target in therapeutic development.

Purpose of the Study:

  • To evaluate the performance of various SBD approaches.
  • To assess their ability to predict binding affinity for human renin inhibitors.
  • To identify optimal modeling tools for structure-based lead optimization.

Main Methods:

  • Assessed multiple SBD computational methods.
  • Utilized co-crystallized small molecule inhibitors of human renin.
  • Focused on predicting binding affinity and discriminating between active/inactive compounds.

Main Results:

  • Most SBD approaches provided qualitative insights into binding.
  • Quantitative accuracy in predicting binding affinity was limited.
  • Decisive discrimination between active and inactive compounds was not consistently achieved.

Conclusions:

  • Current SBD methods need enhancement for reliable lead optimization.
  • Improved modeling is required to capture the physics of ligand-protein binding.
  • Further development is necessary for consistent application in drug discovery projects.